^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ERAS-007

    i
    Company:
    Asana BioSci, Erasca, UT MD Anderson Cancer Center
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    Apply
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2) (NCT04959981)
    Phase 1b
    Erasca, Inc.
    Completed
    Last update posted :
    07/25/2023
    Initiation :
    09/02/2021
    Primary completion :
    04/27/2023
    Completion :
    04/27/2023
    KRAS
    |
    KRAS mutation • EGFR mutation • KRAS G12C
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
    A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) (NCT05279859)
    Phase 1b/2
    Erasca, Inc.
    Withdrawn
    Last update posted :
    06/15/2022
    Initiation :
    03/15/2022
    Primary completion :
    03/01/2025
    Completion :
    06/01/2025
    FLT3
    |
    FLT3 mutation
    |
    Xospata (gilteritinib) • ERAS-007 • ERAS-601
    A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126)
    Phase 1
    Asana BioSciences
    Completed
    Last update posted :
    07/09/2020
    Initiation :
    01/19/2018
    Primary completion :
    06/30/2020
    Completion :
    06/30/2020
    KRAS • HRAS
    |
    KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation
    |
    ERAS-007